Wah Kheong Chan

Noninvasive surrogate endpoints in MASH trials: current perspectives and challenges

Abstract Background Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and liver-related morbidity. Current regulatory pathways rely on histology and long-term clinical outcomes, but repeated liver biopsy is noninvasive and poorly reproducible...